Other news to note for Feb. 25, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Aim Immunotech, Almirall, Alvogen Korea, Beijing Innocare, Beroni, Beximco, Cocrystal, Enlivex, Genetron Health, Glaxosmithkline, Hummingbird Bioscience, Immunoprecise Antibodies, Innovation, Medivir, Mesoblast, Molecular Templates, Mycenax, Mylan, Paratek, Sanofi, Shanghai Hile, Shijiazhuang Yuanmai, Sichuan Clover, Stonewise, Takeda, Viva, Vivus, Wuxi Biologics.

Regulatory front for Feb. 25, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: FDA, COVID-19, Eastgate, India’s Central Drug Standard Control Organization, India’s Directorate of Revenue Intelligence, SEC.

Financings for Feb. 25, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: Biolexis, Canbridge, Outlook.

Clinical data for Feb. 18-24, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Eisai, Harbour Biomed, Immutep, Isofol Medical, Kowa Research Institute, Molecular Templates, Ribomic, Zelira.

Regulatory actions for Feb. 18-24, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Ascentage, Ascletis, Astellas, Bristol-Myers Squibb, Roche, Seattle Genetics, Seqirus, Takeda.

No Comments